This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 1 of 1 for:    Peanut Reactivity Reduced by Oral Tolerance in an anti-IgE Clinical
Previous Study | Return to List | Next Study

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial (PRROTECT)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Children's Hospital of Philadelphia
Stanford University
Ann & Robert H Lurie Children's Hospital of Chicago
Information provided by (Responsible Party):
Lynda Schneider, Boston Children's Hospital
ClinicalTrials.gov Identifier:
NCT01781637
First received: January 30, 2013
Last updated: May 2, 2017
Last verified: May 2017
January 30, 2013
May 2, 2017
January 2013
October 2015   (Final data collection date for primary outcome measure)
Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo [ Time Frame: 6 weeks after last dose of omalizumab/placebo ]
The ability of omalizumab-treated subjects to successfully complete the build-up phase of peanut, and tolerate daily 4,000 mg doses of peanut flour after discontinuing omalizumab. [ Time Frame: 14 wks after the start of oral peanut desensitization (wk 26 of study). ]
Complete list of historical versions of study NCT01781637 on ClinicalTrials.gov Archive Site
Pass 4000 mg OFC 12 Weeks After Last Dose of Omalizumab/Placebo [ Time Frame: 12 weeks after last dose of omalizumab/placebo ]
The ability of subjects to tolerate an oral dose of 4,000 mg peanut. [ Time Frame: 8 wks after the start of oral peanut desensitization (study wk 20). ]
Not Provided
Not Provided
 
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Phase 2 Study of Omalizumab in Oral Peanut Desensitization
The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.

36 subjects will receive Xolair, and 8 subjects will receive placebo. The study will occur at 4 sites: Boston Children's Hospital, Children's Hospital of Philadelphia, Stanford University and Lurie Children's Hospital.

Patients will be pre-treated with Xolair or placebo before rapid oral peanut desensitization. Patients will continue to receive Xolair during the 8 subsequent weeks of desensitization, receiving their final dose of Xolair one week after reaching the highest tolerated dose of peanut.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
  • Peanut Allergy
  • Food Allergy
  • Drug: Omalizumab
    subcutaneous injection
    Other Name: Xolair
  • Drug: placebo
    subcutaneous injection
  • Experimental: omalizumab group
    Patients will receive omalizumab.
    Intervention: Drug: Omalizumab
  • Placebo Comparator: placebo
    Patients will receive placebo.
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
36
October 2017
October 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Moderate to severe peanut allergy-sensitive subjects between the ages of 7 to 25 years old.
  • Sensitivity to peanut allergen will be documented by a positive skin prick test result (6 mm diameter wheal or greater)
  • ImmunoCAP IgE level to peanut > 10 kU/L.
  • Sensitivity to peanut allergen based on a double-blind placebo-controlled oral food challenge (DBPCFC) at maximum of cumulative 175 mg of peanut protein dose.

Exclusion Criteria:

  • Subjects with a total IgE at screening of < 50 kU/L > 2,000 kU/L.
  • Positive reaction to the placebo on DBPCFC.
  • Previous reaction to omalizumab.
  • Subjects having a history of severe anaphylaxis to peanut requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma, or gastrointestinal or gastroesophageal disease.
Sexes Eligible for Study: All
7 Years to 25 Years   (Child, Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01781637
Peanut 002
Yes
Not Provided
Not Provided
Not Provided
Lynda Schneider, Boston Children's Hospital
Boston Children’s Hospital
  • Children's Hospital of Philadelphia
  • Stanford University
  • Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigator: Lynda C Schneider, MD Boston Children’s Hospital
Study Chair: Andrew MacGinnitie, MD, PhD Children' Hospital Boston
Study Chair: Kari Nadeau, MD, PhD Stanford University
Study Chair: Jonathan Spergel, MD, PhD Children's Hospital of Philadelphia
Study Chair: Jacqueline Pongracic, MD Lurie Children's Hospital
Boston Children’s Hospital
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP